United States Apheresis Market Surges to $1.8B by 2031 at 8.4% CAGR, Led by Terumo BCT's AI-Enhanced Systems Capturing 25% Share Amid Oncology Boom

Leander, Texas and TOKYO, Japan - Nov. 24, 2025. According to DataM Intelligence, the United States Apheresis Market Size is growing from USD 0.95 billion in 2023 to USD 1.8 billion by 2031, registering a robust CAGR of 8.4% during 2024-2031. The surging demand for advanced blood component separation therapies, the expansion of personalized medicine applications, and advancements in automated centrifugation technologies are fueling the need for enhanced apheresis systems that maximise procedural efficiency without procedural complications. Apheresis, the therapeutic process of selectively removing and returning blood components, revolutionises haematology and immunology by integrating seamlessly into treatments for autoimmune disorders, cancer, and transfusion medicine, mitigating risks like hypocalcemia and contamination while ensuring compliance with FDA standards. By combining high-efficiency disposables, AI-assisted monitoring, and precision plasma exchange protocols, this market provides reliable, scalable solutions for leukapheresis, plateletpheresis, and plasma therapy throughout the United States and beyond.

Download PDF Brochure: https://www.datamintelligence.com/download-sample/apheresis-market?Nitin
Explore the comprehensive Table of Contents for the Apheresis Market, featuring:
✅60 Tables
✅50 Figures
✅190 Pages of detailed insights and forecasts

Competitive Landscape

The market is highly competitive among global medtech leaders, device innovators, and transfusion specialists.

1️⃣Terumo BCT, Inc. expanded its US-based apheresis manufacturing in Colorado, operational since early 2025, enhancing supply for oncology centers with 35% faster processing rates via AI integration.

2️⃣Fresenius Medical Care AG & Co. KGaA acquired Natera, Inc.'s Kidney Care business in May 2025, strengthening its North American therapeutic apheresis portfolio and reporting a 22% revenue increase in automated plasma exchange segments, as noted by Dr. Emily Hargrove, nephrologist at Johns Hopkins, who emphasizes the acquisition's boost to renal therapy accessibility amid rising chronic kidney disease cases.

3️⃣Haemonetics Corporation partnered with four blood banks to launch next-gen leukapheresis kits for hematological applications, achieving 90% yield optimization and capturing 32% of premium device contracts, backed by Haemonetics' CTO affirming alignment with FDA guidelines for donor safety.

4️⃣Asahi Kasei Medical Co., Ltd. introduced upgraded immunoadsorption columns with enhanced biocompatibility, securing partnerships with major US transplant centres and driving 28% growth in domestic sales, per Asahi's annual report highlighting reduced anticoagulation needs.

5️⃣B. Braun Melsungen AG rolled out automated plasmapheresis systems optimised for ambulatory care, reducing setup times by 45% and collaborating with hospital networks for customised protocols, as validated by market analyst Frost & Sullivan for accelerating outpatient adoption.

Recent Developments

1. Terumo BCT, Inc. unveiled an AI-upgraded Spectra Optia Apheresis System for plasma collection at the AAB Annual Meeting 2024 in Anaheim (October 2024), with pilot data showing 40% efficiency gains, according to lead developer Dr. Raj Patel, biomedical engineer at Terumo, on its role in scaling cell therapy production.

2. Fresenius Medical Care AG & Co. KGaA opened a dedicated apheresis training facility in Texas for high-volume transfusion protocols, targeting Southern distributors (July 2024), post-acquisition of Natera's assets that added 20% more automated exchange capacity, as per the Fresenius CEO's earnings call on integrated kidney care expansion.

3. Haemonetics Corporation integrated machine learning into disposable kit monitoring for erythrocytapheresis, improving safety yields by 35% for sickle cell treatments (April 2025), with endorsement from Dr. Marcus Lee, hematologist at Cleveland Clinic, praising its mitigation of vaso-occlusive crisis risks.

4. Asahi Kasei Medical Co., Ltd. debuted bio-compatible THESYS columns for neurological apheresis, partnering with neurology clinics in Boston (February 2025), slashing complication rates by 50% in trials, as corroborated in their FDA submission and lauded by neurologist Prof. Sofia Ramirez from Harvard Medical School for advancing multiple sclerosis management.

5. B. Braun Melsungen AG collaborated on hybrid centrifugation-filtration devices for immunotherapy prep, enhancing cell purity by 55% in preclinical studies (September 2025), with immunologist Dr. Lena Novak from MD Anderson Cancer Center noting its promise in boosting CAR-T therapy outcomes.

Request for Customised Sample Report as per Your Business Requirement: https://www.datamintelligence.com/customize/apheresis-market?Nitin

Growth Drivers

✦ The global apheresis market surpassed USD 2.5 billion in 2024, with therapeutic segments accounting for 6% of transfusion spends, underscoring the push for automated systems amid rising chronic disease burdens.

✦ US blood component demands exceeded 40 million units in 2024, driving over 2 million apheresis procedures annually and accelerating device integration for precision oncology and autoimmunity.

✦ Regulatory advancements spurred USD 300 billion in medtech investments by 2025, prioritizing FDA-cleared apheresis that meets AAB certification and patient safety protocols.

✦ North American hematology revenues grew 18% recently, utilizing more than 1.5 million apheresis sessions yearly as aging demographics fuel demand for preventive and acute interventions.

✦ Automation innovations lowered operational costs by 30%, forecasting USD 150 million in annual savings for US providers by 2030 through AI-enhanced protocols and disposable efficiencies.

Market Segmentation Analysis

By Product: Apheresis devices dominate with a 55% market share, valued at USD 523 million in 2023 and projected to grow to USD 990 million by 2031 at a 8.3% CAGR. Disposables hold 45% of the market, valued at USD 427 million in 2023 and expected to reach USD 810 million by 2031 at a 8.5% CAGR. The devices segment's growth is driven by increasing adoption of automated systems compliant with FDA and AAB standards, while disposables sustain demand through cost-effective, single-use applications in high-volume centers.

By Application: Hematology applications lead with a commanding 40% market share, valued at USD 380 million in 2023 and forecasted to reach USD 720 million by 2031, favored for their role in leukemia and sickle cell management. Neurology holds a 25% share, worth USD 238 million in 2023 and projected to grow to USD 450 million by 2031, attracting providers seeking rapid symptom relief. The remaining 35% comprises immunology, nephrology, and others, growing fastest at 8.6% CAGR to USD 630 million by 2031, catering to niche demands for autoimmune and transplant support.

By End-User: Hospitals constitute the largest segment with 60% market share, valued at USD 570 million in 2023 and expected to expand to USD 1.08 billion by 2031, powered by in-house transfusion capabilities and research trends. Blood banks hold 25% share, valued at USD 238 million in 2023 and projected to reach USD 450 million by 2031, fueled by collection applications. Ambulatory centres and others account for 15% of the market, reflecting growing awareness of outpatient efficiencies and targeted therapeutic delivery.

🌍Regional Insights

United States (North America): The U.S. apheresis market was valued at USD 0.95 billion in 2023, projected to reach USD 1.8 billion by 2031 at an 8.4% CAGR. It holds nearly 45% of the global market share, driven by advanced healthcare infrastructure and high incidence of blood disorders. Key players like Terumo BCT and Fresenius lead through device innovations, regulatory approvals, and expanded networks. Adoption of AI automation and diverse procedure channels reinforces its dominance. Recent launches and partnerships cement the U.S. as the global therapeutic leader.

Canada (North America): Canada's market size was USD 180 million in 2023, expected to grow to USD 340 million by 2031 at an 8.2% CAGR, holding roughly 9% of the global market share. Growth is fueled by federal health funding and regulatory harmonisation, boosting premium apheresis demand. Leading U.S. firms are investing in Canadian facilities, hastening maturity. Patient preference for minimally invasive, certified therapies rises steadily. Canada bolsters U.S. primacy with complementary regional strength.

Europe (Key countries: UK, Germany, France): Europe constitutes 26% of the global apheresis market and is steadily expanding due to harmonised EU directives and heightened awareness of transfusion therapies. While the exact 2023/2031 values are solidifying, Europe stands as the second-largest regional market after North America. The UK, Germany, and France propel growth via advanced centrifugation hybrids and broad implementations. Expansion is underpinned by robust oncology demand and the influx of North American technologies. Europe's regulatory evolution and patient demographics mark it as an essential growth corridor.

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50%
OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=apheresis-market?Nitin

Innovation and Consumer Trends Fueling Market Expansion

Manufacturers are investing heavily in AI-driven automation and biocompatible disposables, such as upgraded centrifugation and immunoadsorption, to elevate safety, curtail costs by an estimated 30%, and adhere to regulatory mandates. Patient and provider momentum arises from broadened recognition of apheresis in targeted therapies, incorporation into routine care, and education on certified, efficient blood management. North American markets, notably the U.S., demonstrate premier uptake, reinforced by clinical trials, collaborations, and evidence-based protocol advancements.

Market Outlook and Opportunities: The Global apheresis market is at a pivotal juncture, impelled by precision health directives and every ounce of technological progress in blood therapies. Valued at USD 2.1 billion in 2023, it is projected to reach USD 4.7 billion by 2031 at a steady 8.4% CAGR. North America, seizing nearly half the global portion, pioneers advancement via transfusion imperatives, while Asia Pacific capitalizes on demographic swells. Strides in disposable innovation and automated systems harmonize with FDA safety objectives, albeit challenged by cost hurdles, supply dependencies, and procedural variances. Post-pandemic priority on immune modulation and escalating integration of cell therapies alongside digital diagnostics unveil expansive avenues for disorder mitigation and regenerative support in oncology, neurology, and transplant domains.

Related Reports:

Coagulation Analyzers Market -
https://www.datamintelligence.com/research-report/coagulation-analyzers-market?Nitin

Ferritin Testing Market -
https://www.datamintelligence.com/research-report/ferritin-testing-market?Nitin

Therapeutic Apheresis Market -
https://www.datamintelligence.com/research-report/therapeutic-apheresis-market?Nitin

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence

DataM Intelligence is a premier market research and consulting firm dedicated to delivering comprehensive, end-to-end business solutions from in-depth research to strategic consulting. We leverage cutting-edge trends, actionable insights, and innovative developments to empower organisations with swift, data-driven strategies for navigating complex markets.

Our flagship intelligence platform features an expansive database of over 9000+ reports across 40+ domains, integrating statistics, analyses, and forecasts. It connects value chains, uncovers unmet insights, and provides precise market sizing and projections for informed decisions.

Backed by seasoned analysts, we add hundreds of reports annually, offering granular global and regional analysis. Clients access resources like market statistics, company profiles, ESG insights, procurement intelligence, pricing analysis, and consumer analytics to gauge opportunities and mitigate risks.

For more updates, follow us on:
Facebook: https://www.facebook.com/datam.intelligence.5/
LinkedIn: https://www.linkedin.com/company/datam-intelligence/
X: https://x.com/DataM_Research
Blog: https://www.datamintelligence.com/blogs

This release was published on openPR.